GRFS today
$8.43-$0.03 (-0.35%)close Nov 6, 2026Trend
DailyUptrend (starting)
4 hourLeaning Bearish
1 hourLeaning Bearish
15 minSymmetric Triangle
5 minLeaning Bullish
Daily trend turns down below $6.96
Key levels
Resistance$9.09
Resistance$8.76
Support$8.37
Support$7.99
Latest news & SEC filings
NewsFitch keeps Grifols rating, citing steady performance
EarningsGrifols Posts Third-Quarter 2026 Earnings
EarningsGrifols Q3 revenue rises 8.4% to €2.04B, adjusted EBITDA €538M
All GRFS news →About Grifols
Grifols is a healthcare company that makes medicines from human blood plasma, treating conditions such as immune deficiencies, bleeding disorders and emphysema. It gathers plasma at its own donation centers across North America, Europe, the Middle East and Canada, and processes it at plants in those regions. The company also sells laboratory testing products for blood banks and clinical labs, plus hospital infusion and nutrition items. Its customers are hospitals, clinics, blood collection organizations and testing laboratories worldwide.
Based on the company's 20-F filed Apr 17, 2026.
Nasdaq · Healthcare
Grifols SA (GRFS)
What Is the Price Target for GRFS?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is GRFS a Buy or Sell Right Now?
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for GRFS.
Start Free Trial →Is GRFS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward
Fair Value
$21.13
5
Moat Score
NONE
0/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with GRFS?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →GRFS Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for GRFS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for GRFS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:12:32 | $8.43 | 1,300 | $$11K | BUY |
| 20:59:23 | $8.45 | 1,000 | $$8K | MIDPOINT |
| 20:49:41 | $8.45 | 1,800 | $$15K | BUY |
| 20:46:14 | $8.45 | 1,107 | $$9K | BUY |
| 20:07:46 | $8.45 | 1,384 | $$12K | BUY |
5 dark pool trades shown · $$56K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Grifols SA (GRFS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings intelligence, and a complete investment thesis with entry and exit recommendations.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →GRFS — frequently asked questions
What is GRFS stock price today?
Grifols SA (GRFS) is at $8.43, down 0.35% (-$0.03) at the Nov 6, 2026 close.
Why is GRFS stock moving today?
Latest GRFS news — Nov 4, 2026: Fitch keeps Grifols rating, citing steady performance · Nov 2, 2026: Grifols Posts Third-Quarter 2026 Earnings
Did GRFS beat earnings?
GRFS last reported on Jul 28, 2026: EPS $0.25 vs $0.27 expected — a miss of 7.0%.
What are GRFS support and resistance levels?
Support: $8.37, $7.99, $7.71. Resistance: $8.76, $9.09, $9.40.
What are insiders doing with GRFS?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on GRFS?
Nov 4, 2026: Fitch keeps Grifols rating, citing steady performance · Nov 2, 2026: Grifols Posts Third-Quarter 2026 Earnings · Nov 2, 2026: Grifols Q3 revenue rises 8.4% to €2.04B, adjusted EBITDA €538M